Last Updated on July 1, 2021 by The Health Master
Global pharma major Lupin Limited announced the launch of emtricitabine and tenofovir disoproxil fumarate tablets 200 mg/300 mg, having received an approval from the United States Food and Drug Administration (USFDA).
Emtricitabine and tenofovir disoproxil fumarate tablets 200 mg/300 mg, are the generic equivalent of Truvada tablets 200 mg/300 mg, of Gilead Sciences, Inc., and indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
It is also used for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection.
Emtricitabine and tenofovir disoproxil fumarate tablets had estimated annual sales of US$ 2.1 billion in the US, according to IQVIA MAT March 2021.